Zentalis Pharmaceuticals ... (ZNTL)
NASDAQ: ZNTL
· Real-Time Price · USD
1.61
-0.05 (-3.01%)
At close: Oct 03, 2025, 3:59 PM
1.61
0.00%
After-hours: Oct 03, 2025, 06:36 PM EDT
-3.01% (1D)
| Bid | 1.61 |
| Market Cap | 116.14M |
| Revenue (ttm) | 26.86M |
| Net Income (ttm) | -162.78M |
| EPS (ttm) | -2.33 |
| PE Ratio (ttm) | -0.69 |
| Forward PE | -0.8 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 1.7 |
| Volume | 735,067 |
| Avg. Volume (20D) | 747,161 |
| Open | 1.67 |
| Previous Close | 1.66 |
| Day's Range | 1.60 - 1.70 |
| 52-Week Range | 1.01 - 4.44 |
| Beta | 1.77 |
| Ex-Dividend Date | n/a |
About ZNTL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ZNTL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ZNTL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts8 months ago
-21.25%
Zentalis Pharmaceuticals shares are trading lower....
Unlock content with
Pro Subscription
8 months ago
-1.08%
Zentalis Pharmaceuticals shares are trading higher after the company announced that the FDA has granted Fast Track Designation to azenosertib for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
